Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether PD-616 in combination with low-dose
Cytarabine is safe and effective in the treatment of untreated or relapsed/refractory acute
myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).